Four Directors Leave CTI Board
Two Staff Promoted to Senior Management Team
Cell Therapeutics, Inc. (CTI) announced the resignation of four board members -- Silvano Spinelli, executive vice president of development and managing director of European operations for CTI, Erich Platzer, M.D., former chair of Novuspharma, John Fluke, Jr., chair of Fluke Capital Management, LP, a venture capital company, and Max Link, Ph.D., board chair. All resignations are effective immediately, except for Link who will leave at the end of September.
Also announced is the promotion of two vice presidents to executive vice president and to the senior management team. Jade Brown, MBA, was promoted to executive vice president and chief business officer, and Scott Stromatt, M.D., was promoted to executive vice president, clinical development and regulatory affairs. Brown, 37, joined the company in 2004 and Stromatt, 48, in 2002.
"CTI is a different company today than when Novuspharma was acquired and does not need the degree of infrastructure and resources the merger provided," said James A. Bianco, M.D., President and CEO of CTI. "Our focus is getting a new drug application (NDA) for XYOTAX filed and completing an interim analysis on the pixantrone pivotal study. The Company also needs to maintain adequate operating capital to see us through these major milestones. Bringing Jade and Scott onto the senior management team is a sign of our commitment to advance the development and potential commercialization of these late stage products. I look forward to working with the board to bring additional talent to our board of directors."
Spinelli became part of CTI's board as a result of the 2004 merger with Novuspharma. He was a co-founder of Novuspharma and served as its CEO from January 1999 through December 2003. Platzer also joined CTI's board as a result of the Novuspharma merger. He had served as Novuspharma's chair. Fluke joined the board in November 2003. Link joined the board in July 1995 as vice chairman and has served as chairman since January 1996.
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.